Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
Stopped early · Phase 2
Conditions studied: Multiple Myeloma
In brief
This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.
Key facts
- Study ID
- NCT01617213
- Run by
- University of Virginia
- People needed
- 1
- Starts
- 2012-04-01
- Last updated by the study team
- 2013-06-21
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Must be 18 to 75 years of age.
- ECOG performance status of 0, 1 or 2.
- Patients who have a history of another malignant disorder are eligible, provided that they have not received active therapy for 5 years. Patients with basal cell and squamous cell skin cancers are eligible.
- Patients who are pregnant are ineligible.
- Patients must furnish written informed consent and HIPAA authorization for release of personal health information.
- Patients must be able to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments.
- Patients must be HIV and HTLV-I,-II antibody sero-negative.
- Patients must have adequate visceral organ function
You may not qualify if…
- Patients are ineligible if they have received cumulative chemotherapy doses in excess of: carmustine (BCNU) 400 mg/m2, or a cumulative anthracycline exposure in excess of 550 mg/m2 Adriamycin (doxorubicin) unless the gated-pool radionuclide cardiac scan shows greater than/equal to 45% ejection fraction.
- Patients are ineligible if they are receiving any other investigational agents.
Where it is running
- University of Virginia — Charlottesville, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.